{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:29:38.367683+00:00","company":{"ticker":"ORIC","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"024d7e914880017cabe9d5dbb0dadb5289c50c06","cik":1796280,"ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":null},"claim":"Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-26-203993","anchor_url":"https://secwatch.observer/filing/0001193125-26-203993#claim-024d7e914880017cabe9d5dbb0dadb5289c50c06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm"},{"fact_type":"restructuring_charge","fact_key":"77e22eb13a44b8dea76f81ee536f77410ce51636","cik":1796280,"ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","payload":{"affected_area":"discovery research group","charge_text":"approximately $1.9 million","effective_date":"2025-08-12","event_type":"restructuring","headcount_text":"approximately 20% workforce reduction","item_codes_triggered":["2.05"]},"claim":"Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).","evidence_excerpt":"On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-107313","anchor_url":"https://secwatch.observer/filing/0000950170-25-107313#claim-77e22eb13a44b8dea76f81ee536f77410ce51636","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm"},{"fact_type":"earnings_release","fact_key":"151f0df175e6e90880c6d0f954b07ac8cfdae6fd","cik":1796280,"ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"for the quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":null},"claim":"Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-053551","anchor_url":"https://secwatch.observer/filing/0000950170-24-053551#claim-151f0df175e6e90880c6d0f954b07ac8cfdae6fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm"}]}